UMBC Police phone (410-455-5555) main line is back online.
Skip to Main Content

Suzanne Ostrand-Rosenberg, Ph.D.

Professor; Robert and Jane Meyerhoff Chair of Biochemistry

Suzanne Rosenberg

Office: BS 221
Phone: 410-455-2237
Lab: BS 204/205
Lab Phone: 410-455-2251
Email: srosenbe@umbc.edu

Research Group

 

Education

Postdoctoral, Johns Hopkins University, 1977
Ph.D., California Institute of Technology, 1975

Publications

Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S.  2008. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes.  Cancer Immunol. Immunother. 57:389-398.  E-pub ahead of print.
[Abstract]

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.  2007.  Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.  Cancer Res. 67:10019-10026.
[Abstract]

Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S.  2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.  Cancer Res. 67:4507-4513.

Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, and Ostrand-Rosenberg S. Tumor associated myeloid-derived suppressor cells. In:  Cancer Immunotherapy: Immune Suppression and Tumor Growth. (Eds:  George Prendergast and Elizabeth Jaffee.  Chapter 17, p. 309.  Elsevier Inc. June 2007.

Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. 2007.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.  J. Immunol. 179:977-983.
[Abstract]

Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S.  2007.   MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.  Cancer Res. 67:4499-4506.
[Abstract]

Dolan BP, Gibbs KD Jr., and Ostrand-Rosenberg, Suzanne.  2006. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.  J. Immunol. 177:6018-6024
[Abstract]

Bunt SK, Sinha P Clements VK, Leips J and Ostrand-Rosenberg S.  2006.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.  J. Immunol. 176:284-290.
[Abstract]

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML and Ostrand-Rosenberg S.  2006.  Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.  Cancer Res. 66:1147-1154.
[Abstract]

Dolan BP, Gibbs KD Jr., and Ostrand-Rosenberg, Suzanne.  2006. Tumor-specific CD4+ T cells are activated by “cross-dressed” dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.  J. Immunol. 176:1447-1455.
[Abstract]

Ostrand-Rosenberg, S. and P. Sinha, 2008.  Macrophages and Tumor Development.  In:  Tumor-induced immune suppression (D. Gabrilovich and A. Hurwitz, eds.), Springer, pp. 131-155.

Ostrand-Rosenberg, S., 2008.  Immune surveillance:  a balance between protumor and antitumor immunity.  Curr. Opin. Genetics & Devel. 18:1-8
[Abstract]

Ostrand-Rosenberg, S., 2008.  Cancer and complement.  Nature Biotech 26: 1348-1349.
[Abstract] [PDF]

Kundu, N., X. Ma, D. Holt, O. Goloubeva, S. Ostrand-Rosenberg, and A. Fulton, 2008.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.  Breast Cancer Res. Treat. epub ahead of print
[Abstract]

Presentations

Immune Suppression, Inflammation, and Tumor Progression
Medical University of South Carolina
January 8, 2008

Immune Suppression, Inflammation, and Tumor Progression
S. Ostrand-Rosenberg
FDA, Washington, DC
March 7, 2008

Immune surveillance against cancer: a balance between pro- and anti-tumor immunity
Molecular Biology in Clinical Oncology
S. Ostrand-Rosenberg
Aspen, CO (July 11-18, 2008)
July 16, 2009

Uveal melanoma MHC II vaccines activate tumor-specific cytotoxic T cells and block induction of inhibitor costimulatory molecules
International Congress of Eye Research (ICER)
S. Ostrand-Rosenberg, J. Bosch,U. Iheagawara, and M. Srivastava
Beijing, China (Sept. 24-29, 2008)
September 28, 2009

Inflammation-activated myeloid-derived suppressor cells promote tumor progression and metastasis
Chemical and Biological Aspects of Inflammation and Cancer
S. Ostrand-Rosenberg
>ko Olina, Oahu, Hawaii (Oct. 14-17, 2008)
October 17, 2008

Uveal melanoma MHC II vaccines for the treatment of metastatic uveal melanoma
American Association of Ophthalmology and European Society of Ophthalmology Joint Conference
S. Ostrand-Rosenberg, J. Bosch, and U. Iheagawara
Atlanta, GA, Nov. 7-11, 2008
November 11, 2008

Inflammation-drived myeloid-derived suppressor cells: co-opting anti-tumor immunity to promote tumor progression
American Association of Cancer Research: Frontiers in Cancer Prevention
S. Ostrand-Rosenberg
Washington, DC Nov. 16-19, 2008
November 2, 2008

Understanding Cancer
American Association of Cancer Research: Frontiers in Cancer Prevention
S. Ostrand-Rosenberg
Washington, DC Nov. 16-19, 2008
November 18, 2008

Tumor Induced Immune Suppression: The Inflammation Connection
American Association of Cancer Research: Tumor Immunology: New Perspectives
S. Ostrand-Rosenberg
Miami, FL, (Dec. 2-5, 2008)
December 4, 2008